Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.77 |
| ▸ | PDE6C | P51160 | 2/20 | 0.77 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.57 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7959160 | 0.95 | PDE5A (0.77) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL2693448 | 0.94 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL29357402 | 0.94 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL29611957 | 0.92 | PDE5A (0.90) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL146830 | 0.92 | PDE5A (0.90) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL25013469 | 0.90 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL30199753 | 0.90 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL7965731 | 0.89 | PDE5A (0.84) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL28482244 | 0.88 | PDE5A (0.83) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL7964961 | 0.88 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210289832-A1 | LIPOPHILIC ACTIVE AGENT INFUSED TOBACCO LEAVES AND/OR TOBACCO MATERIALS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210145036-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | Poviva Corp. | 2021-05-20 | — | — | US | disclosed |
| US-20200323773-A1 | FOOD AND BEVERAGE COMPOSITIONS COMPRISING PDE5 INHIBITORS | Poviva Corp. | 2020-10-15 | — | — | US | disclosed |
| US-20200178572-A1 | MICROWAVE PROCESSING METHODS FOR FORMULATING ORALLY INGESTIBLE COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE AGENTS | Poviva Corp. | 2020-06-11 | — | — | US | disclosed |
| US-20160263120-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160263120-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263120-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | PDE5A, PDE3A, PDE12 | PDE5A 1/4885PDE6C 21/4885HDAC1 2431/4885 |
| US-20200323773-A1 | FOOD AND BEVERAGE COMPOSITIONS COMPRISING PDE5 INHIBITORS | PDE5A, PDE3A, PDE3B | PDE5A 1/4885PDE6C 24/4885HDAC1 1031/4885 |
| US-20200178572-A1 | MICROWAVE PROCESSING METHODS FOR FORMULATING ORALLY INGESTIBLE COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE AGENTS | PNLIP, LIPC, LIPA | PDE5A 2615/4885PDE6C 2592/4885HDAC1 2159/4885 |
| US-20210145036-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | LIPC, PNLIP, LIPA | PDE5A 2948/4885PDE6C 3469/4885HDAC1 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.